Restricted
Sotrovimab has shown reduced neutralization activity in vitro against the Omicron BA.2 variant. As of May 2022, 70% of samples tested in PEI were the BA.2 variant.
These recommendations are largely based on clinical trials evaluating treatment of outpatients with mild COVID-19 illness at high-risk of severe disease